PharmGen Science, Inc.
Financials
Valuation Metrics
PharmGen Science, Inc.'s Market Cap is ₩646B. At end of 2025 it was ₩941B. Ranked #1607 of 2,421 in KR market (top 66%), #657 of 781 on KOSPI (top 84%), #176 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 76%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 64.56B KRW | KR#1,607/2,421 Sec#176/231 |
| Revenue | 175.36B KRW | KR#1,102/2,421 Sec#66/231 |
| Net Income | -134.36B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 184.19B KRW | KR#1,370/2,421 Sec#101/231 |
| Net Assets | 140.04B KRW | KR#1,181/2,421 Sec#88/231 |
| Employees | 254 | KR#919/2,421 Sec#79/231 |
| Value | ||
| P/B | 0.46x | KR#714/2,421 Sec#30/231 |
| P/S | 0.37x | KR#715/2,421 Sec#21/231 |
| EV/EBITDA | 10.76x | KR#660/2,421 Sec#31/231 |
| FCF Yield | 5.97% | KR#787/2,421 Sec#38/231 |
| Profitability | ||
| ROE | -95.95% | KR#2,339/2,421 Sec#215/231 |
| ROA | -72.95% | KR#2,385/2,421 Sec#223/231 |
| Op. Margin | 2.39% | KR#1,329/2,421 Sec#96/231 |
| Revenue Growth | 0.42% | KR#1,504/2,421 Sec#149/231 |
| Earnings Growth | -3582.94% | KR#1,346/2,421 Sec#96/231 |
| Financial Health | ||
| Debt Ratio | 31.53% | KR#616/2,421 Sec#72/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | 3.86B KRW | KR#966/2,421 Sec#68/231 |
| Cash | 19.52B KRW | KR#1,268/2,421 Sec#94/231 |
| Current Ratio | 3.33x | KR#495/2,421 Sec#73/231 |
| Net Debt/EBITDA | -4.66x | KR#107/2,421 Sec#3/231 |
| Performance | ||
| 1Y Return | -36.67% | KR#1,754/2,421 Sec#144/231 |
| 1M Return | -10.09% | KR#2,101/2,421 Sec#175/231 |
| From 52W High | -38.44% | KR#853/2,421 Sec#58/231 |
| 1Y MDD | -40.96% | KR#618/2,421 Sec#43/231 |
| Trading | ||
| Volume | 26,035 shares | KR#1,453/2,421 Sec#145/231 |
| Trading Value | 74.0M KRW | KR#1,687/2,421 Sec#172/231 |
| Foreign Own. | 1.67% | KR#1,767/2,421 Sec#171/231 |
| Per Share | ||
| EPS | -5,931 KRW | KR—/2,421 Sec—/231 |
| BPS | 6,182 KRW | KR#1,343/2,421 Sec#93/231 |
Company Info
Established in 1966 as Sudo Pharmaceutical Industry, this company engages in digestive system therapeutics and health functional foods. With headquarters and production facilities in Hwaseong, Gyeonggi-do, it operates wholesale and national branches, a global R&D center, and a development division, focusing on selling professional and general pharmaceuticals and new drug development. In 2021, it established a biosimilar new drug division and recruited experts, and in 2022, announced its R&D Vision 2030, aiming to become a specialized company in digestive system new drug development.